Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Les Laboratoires Servier

Egis Gyogyszergyar Rt.

Márta Porcs-Makkay

Tibor Mezei

Gyula Simig

Balázs Volk

Kálmán Nagy

Gyula Lukács

Attila Mandi

József Barkóczy

Ferenc Lorant Bartha

Gyula Lukacs

Jozsef Barkoczy

Tibor Szabo

Balazs Volk

Laszlo Pongo

György Lévay

Enikó Molnár

Péter Trinka

Gyorgy Krasznai

Adrienn Keszthelyi

Györgyi Vereczkeyné Donáth

Gábor Gigler

Zsuzsanna Szent-Királlyi

Gyorgy Ruzsics

Maria Tothne Lauritz

Gyuláné Körtvélyessy

Bálint Nyulasi

Mátyás Milen

Tamás Gregor

János Szulágyi

Éva Pécsi

Norbert Mesterházy

Zoltán Katona

László Pongó

Hajnalka Kompagne

Judit Broda

Jozsef Debreczeni

Angéla Pandur

Mária Vajjon

György Ruzsics

Guyla Simig

Zsuzsanna Évinger

Lászlö Pongo

Györgyi Vereczekeyné Donath

Enikö Molnár

Angéla Veressné Pandur

József Debreczeni

György Krasznai

Valéria Hofmanné Fekete

Enikö Molnar

Enikõ Molnár

Jószef Barkóczy

Gyula Lucáks

László Gábor Hársing

József Schindler

István Gacsalyi

Katalin Pallagi

Ildikó Nagyné Gyönös

András Egyed

Gábor Szénási

Elemér Fogassy

Tibor SzabÓ

Maria TÓTHNÉ Lauritz

Ferenc Lóránt Bartha

The object of the present invention is a process for preparing the 2-acetoxi-5-(2-fluor-&#x3b1;-cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-thieno[3,2-c]pyridine (prasugrel) of the formula (I). The process starts from crystalline 5-trityl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine of the formula (VI). Further objects of the present invention are two novel crystalline forms of 5-trityl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine of the formula (VI) and the use thereof for preparing the compound of the formula (V) and process preparing thereof.

Process for preparing pharmaceutical compounds and intermediate compounds

The present invention is related to methods for the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S,6E)-dihydroxy-hept-6-enoic acid, intermediates thereof and methods for producing said intermediates.

Method for preparing rosuvastatin salts

The invention relates to a process for the preparation of cyclopropyl benzyl ketone compounds of formula (II) wherein Rrepresents fluorine or chlorine atom or Calkoxy group, by the reaction of a Grignard reagent, obtained from the reaction of compound of formula (V), wherein X represents chlorine or fluorine atom, with the compound of formula (IV), wherein Rrepresents Calkyl group, having a straight or branched chain. The process can be applied preferably on industrial scale. Compound of formula (II), wherein R represents a fluorine atom in position 2 is an intermediate of the preparation process of prasugrel, which is a platelet inhibitor used in the therapy. 

Process for the preparation of pharmaceutical intermediates

The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium sait monohydrate is produced. Said sait is subsequently treated with mineral or organic acid to yield high-purity meloxicam.

Process for preparation of high-purity meloxicam and meloxicam potassium salt

The compounds of the general Formula (I), wherein Ris aryl or alkyl; Rrepresents alkyl; Rrepresents alkyl or aralkyl, are valuable pharmaceutical intermediates, which can be prepared by reacting a compound of the general Formula (IV) (wherein the definitions of Rand Rare as above), with at least 2 molar equivalents of the compound of the general Formula (VI) (wherein X represents halogen or tertiary butyloxycarbonyloxy group and Ris as defined above). The known compounds of the general Formula (II) (wherein Rand Rare as defined above) are prepared by reacting the compounds of the general Formula (I) with thionyl chloride. The compounds of the general Formula (I) are new intermediates useful in the synthesis of pharmaceutically active ingredients, particularly in the preparation of ACE-inhibitors, e.g. enalapril, perindopril or ramipril.

Pharmaceutical intermediate for synthesizing ACE inhibitors and the use thereof

The present invention is related to 1-[(4-chlorophenyl)-phenylmethyl]-4-(2,2,2-trichloroethoxycarbonyl)-piperazine of the Formula (IV) and optically isomers thereof, process for preparation thereof and the use of the compound of the Formula (IV) in the preparation of 1-(4-chlorophenyl)-phenylmethyl-piperazine and optical isomers and salts thereof. 1-(4-chlorophenyl)-phenylmethyl-piperazine and optical isomers thereof are important intermediates in the preparation of non-sedating antihistamine-type active pharmaceutical ingredients. 

Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates

The invention relates to 1-{2(S)-[1(S)-(ethoxycarbonyl)butylamino]propionyl}-(3aS,7aS)octahydroindol-2(S)-carboxylic acid of the Formula I and the t-butylamine salt of the Formula I' thereof free of contaminations derivable from dicyclohexyl carbodiimide, and a process for the preparation thereof. The invention also relates to new intermediates of the general Formula III (wherein R stands for lower alkyl or aryl lower alkyl). The compound of the Formula I&#x2014;perindopril&#x2014;is a known ACE inhibitor.

Process for the preparation of high purity perindopril and intermediates useful in the synthesis

Process for the preparation of high purity perindopril

Process for the industrial synthesis of the compounds of formula (I): wherein Rrepresents a hydrogen atom or an alkyl or benzyl group, and Rrepresents a group that protects the amino function.

[object Object]

Growing community of inventors

Pomáz, Hungary

Márta Porcs-Makkay